Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.

Regulatory T cells (Tregs) are key modulators of inflammation and are important for the maintenance of peripheral tolerance. Adoptive immunotherapy with polyclonal Tregs holds promise in organ transplantation, graft-versus-host disease, and autoimmune diseases, but may be enhanced by antigen-specific, long-lived Treg cells. We modified primary human Tregs with chimeric antigen-receptors (CARs) bearing different costimulatory domains and performed in vitro analyses of their phenotype and function. While neither the presence of a CAR nor the type of costimulation domain influenced Foxp3 expression in Tregs, the costimulation domain of the CARs affected CAR Treg surface phenotype and functions such as cytokine production. Furthermore, signaling from the CD28 costimulation domain maintained CAR Treg suppressor function, whereas 4-1B costimulation did not. In vivo, CAR Tregs accumulated at sites expressing target antigen, and suppressed antigen specific effector T cell responses; however, only CAR Tregs with CD28 signaling domains were potent inhibitors of effector T cell mediated graft rejection in vivo. Our findings support the use of CD28 based CAR-Tregs for tissue specific immune suppression in the clinic.

[1]  Matthew J. Frigault,et al.  Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. , 2018, Blood.

[2]  M. Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[3]  D. Hafler,et al.  Regulatory T cells in autoimmune disease , 2018, Nature Immunology.

[4]  M. Ansari,et al.  A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants , 2018, Scientific Reports.

[5]  C. June,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[6]  W. Haining,et al.  Comparative transcriptome analysis reveals distinct genetic modules associated with Helios expression in intratumoral regulatory T cells , 2018, Proceedings of the National Academy of Sciences.

[7]  Jörn Walter,et al.  CD137+CD154− Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures , 2018, Front. Immunol..

[8]  Ying Hu,et al.  TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance , 2017, Science Translational Medicine.

[9]  M. Levings,et al.  Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells , 2017, Front. Immunol..

[10]  J. Orange,et al.  Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. , 2017, Cell reports.

[11]  F. Vincenti,et al.  Transplant trials with Tregs: perils and promises. , 2017, The Journal of clinical investigation.

[12]  F. Watt,et al.  Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  S. Riddell,et al.  Fully human CD19-specific chimeric antigen receptors for T-cell therapy , 2017, Leukemia.

[14]  D. Scott,et al.  FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. , 2017, Blood.

[15]  J. Bluestone,et al.  Regulatory T cell therapy for type 1 diabetes: May the force be with you. , 2016, Journal of autoimmunity.

[16]  M. Levings,et al.  How antigen specificity directs regulatory T‐cell function: self, foreign and engineered specificity , 2016, HLA.

[17]  M. Levings,et al.  Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. , 2016, The Journal of clinical investigation.

[18]  C. Le,et al.  Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. , 2016, Blood.

[19]  Brian Keith,et al.  Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.

[20]  Jeffrey A. Bluestone,et al.  Type 1 diabetes immunotherapy using polyclonal regulatory T cells , 2015, Science Translational Medicine.

[21]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[22]  R. Kaplan,et al.  4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors , 2015, Nature Medicine.

[23]  Na Li,et al.  Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.

[24]  S. Sakaguchi,et al.  TREG-cell therapies for autoimmune rheumatic diseases , 2014, Nature Reviews Rheumatology.

[25]  B. Falini,et al.  HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. , 2014, Blood.

[26]  Jonathan H. Esensten,et al.  microRNA-17–92 Regulates IL-10 Production by Regulatory T Cells and Control of Experimental Autoimmune Encephalomyelitis , 2013, The Journal of Immunology.

[27]  D. Bigner,et al.  Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody , 2013, Cancer Immunology Research.

[28]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[29]  E. Shevach Application of IL-2 therapy to target T regulatory cell function. , 2012, Trends in immunology.

[30]  W. Kastenmuller,et al.  Foxp3+ Regulatory T-cells and IL-2: The Moirai of T-cell Fates? , 2012, Front. Immun..

[31]  D. Vignali Mechanisms of Treg Suppression: Still a Long Way to Go , 2012, Front. Immun..

[32]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[33]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[34]  J. Spencer,et al.  Antibodies to human IL-10 neutralize ebvIL-10-mediated cytokine suppression but have no effect on cmvIL-10 activity. , 2010, Virus research.

[35]  K. Wood,et al.  In vivo Prevention of Transplant Arteriosclerosis by ex vivo Expanded Human Regulatory T Cells , 2010, Nature Medicine.

[36]  T. Kelley,et al.  Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway , 2009, BMC Immunology.

[37]  T. Schumacher,et al.  Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis , 2009, Proceedings of the National Academy of Sciences.

[38]  S. Sakaguchi,et al.  Regulatory T cells: how do they suppress immune responses? , 2009, International immunology.

[39]  D. Campana,et al.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  J. Sprent,et al.  In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression , 2009, The Journal of experimental medicine.

[41]  J. Wagner,et al.  Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. , 2008, Blood.

[42]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[43]  T. Ley,et al.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. , 2007, Immunity.

[44]  X. Wang,et al.  Agonistic Anti‐4‐1BB Antibody Promotes the Expansion of Natural Regulatory T Cells While Maintaining Foxp3 Expression , 2007, Scandinavian journal of immunology.

[45]  S. Larson,et al.  Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.

[46]  Alexander Perl,et al.  A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. , 2006, Blood.

[47]  David C. Gondek,et al.  Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism1 , 2005, The Journal of Immunology.

[48]  T. Malek,et al.  Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.

[49]  Ethan M. Shevach,et al.  Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function , 2004, The Journal of Immunology.

[50]  J. Bae,et al.  4‐1BB‐dependent inhibition of immunosuppression by activated CD4+CD25+ T cells , 2004, Journal of leukocyte biology.

[51]  C. Fathman,et al.  Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.

[52]  David Klatzmann,et al.  CD4+CD25+ Immunoregulatory T Cells , 2002, The Journal of experimental medicine.

[53]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[54]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[55]  M. Toda,et al.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.

[56]  E. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[57]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Arthur Weiss,et al.  The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways , 1991, Cell.

[59]  S. Sakaguchi Regulatory T cells: history and perspective. , 2011, Methods in molecular biology.

[60]  Z. Eshhar,et al.  The T-body approach: potential for cancer immunotherapy , 2004, Springer Seminars in Immunopathology.